Axelyf

United States · Biotech

Axelyf develops RNA medicines for cancer and autoimmune diseases using its lipid nanoparticle delivery platform.

Platform

Its AXL lipid nanoparticle platform delivers RNA payloads into cells. The company uses its ANNA AI model to guide lipid design.

Programs

Its development pipeline includes AX-004, an in vivo CAR-T program targeting solid tumors, and AX-003 for autoimmune hepatitis. These are development programs rather than marketed treatments.

Funding history

1 round · 0 with disclosed amounts
AnnouncedRoundAmountInvestors
Equity offering with founder debt conversionsUndisclosedParticipants not disclosed
Sourcesaxelyf.com ↗